---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-26-000034"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:10:34.643129+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B

## Summary
- FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.
- GAAP net income $4.0B in FY2025 vs net loss of $(536)M in 2024; cash $12.3B.
- FY2026 revenue guidance $12.95–$13.1B; non-CF product revenue expected ≥$500M.
- JOURNAVX: >550,000 prescriptions filled in 2025; coverage for >200M U.S. lives.
- Rolling BLA for povetacicept in IgAN on track for completion in H1 2026; ALYFTREK pediatric study completed.

## SEC filing metadata
- accession: 0000875320-26-000034
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/0000875320-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/vrtx-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-26-000034
- JSON: https://secwatch.observer/filing/0000875320-26-000034.json
- Plain text: https://secwatch.observer/filing/0000875320-26-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.